Can α-synuclein be targeted in novel therapies for Parkinson’s disease?

References

• Chaudhuri KR, Healy DG, Schapira AH. Non-motor symptoms of Parkinson’s disease: diagnosis and management. Lancet Neurol.5(3), 235–245 (2006).
   PubMed Web of Science ®Google Scholar
• Lang AE. Clinical trials of disease-modifying therapies for neurodegenerative diseases: the challenges and the future. Nature Med.16(11), 1223–1226 (2010).
   PubMed Web of Science ®Google Scholar
• Shults CW. Lewy bodies. Proc. Natl Acad. Sci. USA103(6), 1661–1668 (2006).
   PubMed Web of Science ®Google Scholar
• Chu Y, Kordower JH. Age-associated increases of α-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: is this the target for Parkinson's disease? Neurobiol. Dis.25(1), 134–149 (2007).
   PubMed Web of Science ®Google Scholar
• Simon-Sanchez J, Schulte C, Bras JM et al. Genome-wide association study reveals genetic risk underlying Parkinson’s disease. Nature Genet.41(12), 1308–1312 (2009).
   PubMed Web of Science ®Google Scholar
• Venda LL, Cragg SJ, Buchman VL, Wade-Martins R. α-synuclein and dopamine at the crossroads of Parkinson's disease. Trends Neurosci.33(12), 559–568 (2010).
   PubMed Web of Science ®Google Scholar
• Singleton AB, Farrer M, Johnson J et al. α-Synuclein locus triplication causes Parkinson's disease. Science302(5646), 841 (2003).
   PubMed Web of Science ®Google Scholar
• Scherzer CR, Grass JA, Liao Z et al. GATA transcription factors directly regulate the Parkinson’s disease-linked gene α-synuclein. Proc. Natl Acad. Sci. USA105(31), 10907–10912 (2008).
   PubMed Web of Science ®Google Scholar
• Fountaine TM, Venda LL, Warrick N et al. The effect of α-synuclein knockdown on MPP+ toxicity in models of human neurons. Eur. J. Neurosci.28(12), 2459–2473 (2008).
   PubMedGoogle Scholar
• Sapru MK, Yates JW, Hogan S, Jiang L, Halter J, Bohn MC. Silencing of human α-synuclein in vitro and in rat brain using lentiviral-mediated RNAi. Exp. Neurol.198(2), 382–390 (2006).
   PubMed Web of Science ®Google Scholar
• Mccormack AL, Mak SK, Henderson JM, Bumcrot D, Farrer MJ, Di Monte DA. α-synuclein suppression by targeted small interfering RNA in the primate substantia nigra. PloS One5(8), e12122 (2010).
   PubMed Web of Science ®Google Scholar
• Burre J, Sharma M, Tsetsenis T, Buchman V, Etherton MR, Sudhof TC. α-synuclein promotes SNARE-complex assembly in vivo and in vitro. Science329(5999), 1663–1667 (2010).
   PubMed Web of Science ®Google Scholar
• Eriksen JL, Przedborski S, Petrucelli L. Gene dosage and pathogenesis of Parkinson’s disease. Trends Mol. Med.11(3), 91–96 (2005).
   PubMed Web of Science ®Google Scholar
• Gorbatyuk OS, Li S, Nash K et al. In vivo RNAi-mediated α-synuclein silencing induces nigrostriatal degeneration. Mol. Ther.18(8), 1450–1457 (2010).
   PubMed Web of Science ®Google Scholar
• Madine J, Middleton DA. Targeting α-synuclein aggregation for Parkinson's disease treatment. Drugs Fut.34 (2009).
   Google Scholar
• Xilouri M, Stefanis L. Autophagic pathways in Parkinson disease and related disorders. Expert Rev. Mol. Med.13, e8 (2011).
   PubMedGoogle Scholar
• Kordower JH, Chu Y, Hauser RA, Freeman TB, Olanow CW. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson’s disease. Nature Med.14(5), 504–506 (2008).
   PubMed Web of Science ®Google Scholar
• Li JY, Englund E, Holton JL et al. Lewy bodies in grafted neurons in subjects with Parkinson’s disease suggest host-to-graft disease propagation. Nature Med.14(5), 501–503 (2008).
   PubMed Web of Science ®Google Scholar
• Brundin P, Li JY, Holton JL, Lindvall O, Revesz T. Research in motion: the enigma of Parkinson’s disease pathology spread. Nature Rev.9(10), 741–745 (2008).
   Web of Science ®Google Scholar
• Lee HJ, Suk JE, Bae EJ, Lee JH, Paik SR, Lee SJ. Assembly-dependent endocytosis and clearance of extracellular α-synuclein. Int. J. Biochem. Cell Biol.40(9), 1835–1849 (2008).
   PubMed Web of Science ®Google Scholar
• Lee SJ. Origins and effects of extracellular α-synuclein: implications in Parkinson's disease. J. Mol. Neurosci.34(1), 17–22 (2008).
   PubMedGoogle Scholar
• Hansen C, Angot E, Bergstrom AL et al. α-synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells. J. Clin. Invest.121(2), 715–725 (2011).
   PubMed Web of Science ®Google Scholar
• Desplats P, Lee HJ, Bae EJ et al. Inclusion formation and neuronal cell death through neuron-to-neuron transmission of α-synuclein. Proc. Natl Acad. Sci. USA106(31), 13010–13015 (2009).
   PubMed Web of Science ®Google Scholar
• Emmanouilidou E, Melachroinou K, Roumeliotis T et al. Cell-produced α-synuclein is secreted in a calcium-dependent manner by exosomes and impacts neuronal survival. J. Neurosci.30(20), 6838–6851 (2010).
   PubMed Web of Science ®Google Scholar
• Luk KC, Song C, O’Brien P et al. Exogenous α-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells. Proc. Natl Acad. Sci. USA106(47), 20051–20056 (2009).
   PubMed Web of Science ®Google Scholar
• Braak H, Ghebremedhin E, Rub U, Bratzke H, Del Tredici K. Stages in the development of Parkinson’s disease-related pathology. Cell Tissue Res.318(1), 121–134 (2004).
   PubMed Web of Science ®Google Scholar
• Postuma RB, Gagnon JF, Montplaisir J. Clinical prediction of Parkinson’s disease: planning for the age of neuroprotection. J. Neurol. Neurosurg. Psychiatry81(9), 1008–1013 (2010).
   PubMed Web of Science ®Google Scholar
• Hawkes CH, Del Tredici K, Braak H. Parkinson’s disease: a dual-hit hypothesis. Neuropathol. Appl. Neurobiol.33(6), 599–614 (2007).
   PubMed Web of Science ®Google Scholar
• Angot E, Steiner JA, Hansen C, Li JY, Brundin P. Are synucleinopathies prion-like disorders? Lancet Neurol.9(11), 1128–1138 (2010).
   PubMed Web of Science ®Google Scholar
• Masliah E, Rockenstein E, Adame A et al. Effects of α-synuclein immunization in a mouse model of Parkinson's disease. Neuron46(6), 857–868 (2005).
   PubMed Web of Science ®Google Scholar